Doxetaxel과 Adiramycine을 이용한 수술전 항암화학요법; 반응률에 영향을 미치는 임상병리학적 인자 (Neoadjuvant chemotherapy with Docetaxel and Adriamycin in breast cancer; Clincopathologic factors influencing to response rate)

서지정보

· 발행기관 : 한국유방암학회
· 수록지 정보 : Journal of Breast Cancer / 11권 / 2호 / 89 ~ 94페이지
· 저자명 : 류동원, 전창완, 이충한

초록

Purpose: The objective of this study was to test the efficacy and toxicity of adriamycin plus docetaxel as the primary chemotherapy for women with advanced breast carcinoma, and including those patients with inflammatory breast cancer. Our study also evaluated the clinicopathologic factors influencing the response rate to neoadjuvant chemotherapy.
Methods: 28 patients who underwent neoadjuvant chemotherapy between 2001 and 2003 were included for this study. The patients were treated with adriamycin(50 mg/m2; intravenous bolus) followed by docetaxel (75mg/m2; 1-hour intravenous infusion) on the first day of each cycle for an average four cycles. We analysed the response rate to adjuvant chemotherapy by reviewing the post operative pathologic report. Additionally we compared the clincopathologic factors related to the response rate. Statistical analyses were performed with χ2-tests and using SPSS 11.0
Results: The mean age at diagnosis was 48.9 years old(range 29~63). The tumoral response to neoadjuvant chemotherapy was, 3 patients(10%) showed a CR(complete response), 21 patients(73.3%) showed a PR(partial response). and which about lymph node were that 7 patients(23.3%) have shown CR, 16 patients(56.6%) have shown PR. The overall response rate to neoadjuvant chemotherapy was 87.5%. The preoperative serum-CEA level was influenced the response rate to neoadjuvant chemotherapy(p=0.014). Grade 3 or 4 neutropenia was recorded in 81.9% of the patients(59/72). Grade 3 or 4 anemia was recorded in 2.8% of the patients.
Conclusion: Neoadjuvant chemotherapy with adriamycin plus docetaxel was effective treatment for patients with locally advanced breast cancer. The preoperative serum CEA level colud be the important factor for the neoadjuvant chemotherapy response rate.

영어초록

Purpose: The objective of this study was to test the efficacy and toxicity of adriamycin plus docetaxel as the primary chemotherapy for women with advanced breast carcinoma, and including those patients with inflammatory breast cancer. Our study also evaluated the clinicopathologic factors influencing the response rate to neoadjuvant chemotherapy.
Methods: 28 patients who underwent neoadjuvant chemotherapy between 2001 and 2003 were included for this study. The patients were treated with adriamycin(50 mg/m2; intravenous bolus) followed by docetaxel (75mg/m2; 1-hour intravenous infusion) on the first day of each cycle for an average four cycles. We analysed the response rate to adjuvant chemotherapy by reviewing the post operative pathologic report. Additionally we compared the clincopathologic factors related to the response rate. Statistical analyses were performed with χ2-tests and using SPSS 11.0
Results: The mean age at diagnosis was 48.9 years old(range 29~63). The tumoral response to neoadjuvant chemotherapy was, 3 patients(10%) showed a CR(complete response), 21 patients(73.3%) showed a PR(partial response). and which about lymph node were that 7 patients(23.3%) have shown CR, 16 patients(56.6%) have shown PR. The overall response rate to neoadjuvant chemotherapy was 87.5%. The preoperative serum-CEA level was influenced the response rate to neoadjuvant chemotherapy(p=0.014). Grade 3 or 4 neutropenia was recorded in 81.9% of the patients(59/72). Grade 3 or 4 anemia was recorded in 2.8% of the patients.
Conclusion: Neoadjuvant chemotherapy with adriamycin plus docetaxel was effective treatment for patients with locally advanced breast cancer. The preoperative serum CEA level colud be the important factor for the neoadjuvant chemotherapy response rate.

참고자료

· 없음